{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:28:15Z","timestamp":1784734095324,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently, the therapeutic treatment of differentiated thyroid carcinoma (DTC) is based on the use of radioactive iodine; the effectiveness of treatment depends on the sensitivity of tumor cells to therapy. Factors associated with a high risk of radioactive iodine resistance of DTC (RAIR-DTC) are poorly understood in the current literature, but understanding their role may help optimize patient care. The aim of our study is to assess the relationship between the clinical and pathological characteristics of DTC and the risk of radioiodine resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a case-control study involving a targeted sample of patients with differentiated thyroid carcinoma (DTC). The study included a total of 373 patients, of whom 60 were radioiodine-resistant and 313 were radioiodine-sensitive. For the molecular analysis, an additional sub-cohort was selected from the overall sample (n = 167), in which mutations in BRAF V600E, NRAS (codon 61) and pTERT (C228T\/C250T) were determined using ddPCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the group of patients with RAIR-DTC, total thyroidectomy with radical lymph node dissection was performed twice as often, which indicates more aggressive tumor invasion in this category of patients (p&amp;lt;0.001). The main risk factors for RAIR-DTC were female gender, total thyroidectomy with radical lymph node dissection, the presence of metastases in the lymph nodes, the total radiation dose, the absence of distant metastases, and the total number of lymph nodes removed, in the histological subcohort (n = 167), the presence of the double BRAF+pTERT mutation was also identified. Multivariate regression analysis showed that statistically significant risk factors for radioiodine resistance were the total radiation dose, the absence of distant metastases, and the total number of removed lymph nodes. These results were confirmed by ROC analysis; AUC was 0.796 (95% CI 0.726-0.865), p&amp;lt;0.0001.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The obtained data highlight the interplay between clinical and molecular factors in the development of radioiodine resistance in differentiated thyroid cancer (DTC). The co-occurrence of BRAF and TERT mutations has potential prognostic significance. These findings suggest that integrating clinical and molecular data enables more accurate risk stratification for radioiodine resistance and helps define the direction of future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1709736","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:35:12Z","timestamp":1773207312000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Aidana","family":"Rakhmankulova","sequence":"first","affiliation":[{"name":"Semey Medical University","place":["Semey, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pak","sequence":"additional","affiliation":[{"name":"National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Pivina","sequence":"additional","affiliation":[{"name":"Semey Medical University","place":["Semey, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhandos","family":"Burkitbayev","sequence":"additional","affiliation":[{"name":"National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Orekhov","sequence":"additional","affiliation":[{"name":"Semey Medical University","place":["Semey, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Pak","sequence":"additional","affiliation":[{"name":"Astana Vision","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saltanat","family":"Bolsynbekova","sequence":"additional","affiliation":[{"name":"National Research Oncology Center","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim","family":"Pivin","sequence":"additional","affiliation":[{"name":"Medical Centre Hospital of the President\u2019s Affairs Administration of the Republic of Kazakhstan","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Seitkhanova","sequence":"additional","affiliation":[{"name":"Semey Medical University","place":["Semey, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kairzhan","family":"Kudaiberdinov","sequence":"additional","affiliation":[{"name":"Semey Medical University","place":["Semey, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altay","family":"Dyussupov","sequence":"additional","affiliation":[{"name":"Semey Medical University","place":["Semey, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Head of the Department of Oncology and Molecular Diagnostic Pathology, Nagasaki University","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.110","article-title":"The changing incidence of thyroid cancer","volume":"12","author":"Kitahara","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0484","article-title":"Thyroid cancer: risk-stratified management and individualized therapy","volume":"22","author":"Raue","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B3","unstructured":"2021"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04084","article-title":"Trends and projections of the global burden of thyroid cancer from 1990 to 2030","volume":"14","author":"Hu","year":"2024","journal-title":"J Glob Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1501993","article-title":"Biological and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0173","article-title":"Multi-organ distant metastases confer worse disease- specific survival in differentiated thyroid cancer","volume":"24","author":"Wang","year":"2014","journal-title":"Thyroid."},{"key":"B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2265.2005.02304.x","article-title":"Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome","volume":"63","author":"Haq","year":"2005","journal-title":"Clin Endocrinol (Oxf)."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000349","article-title":"Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer","volume":"29","author":"Ibrahim","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"B10","article-title":"New approaches in the management of radioiodine-resistance thyroid cancer: the molecular targeted therapy era","volume":"9","author":"Capdevila","year":"2010","journal-title":"Discov Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091382","article-title":"Radioiodine-resistance thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies","volume":"11","author":"Aashiq","year":"2019","journal-title":"Cancers (Basel)."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1590\/s0100-879x2010007500120","article-title":"Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma","volume":"44","author":"Coelho","year":"2011","journal-title":"Braz J Med Biol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/921682","article-title":"New targeted molecular therapies for dedifferentiated thyroid cancer","volume":"921682","author":"Antonelli","year":"2010","journal-title":"J Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0107","article-title":"Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas","volume":"21","author":"Wassermann","year":"2016","journal-title":"Oncologist."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101013","article-title":"Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance","volume":"72","author":"Shen","year":"2024","journal-title":"Drug Resist Updat."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0038","article-title":"Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma","volume":"26","author":"Scheffel","year":"2016","journal-title":"Thyroid."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B20","article-title":"Radioiodine refractory differentiated thyroid cancer","author":"Boudina","year":"2023","journal-title":"Hell J Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03336-4","article-title":"The 5th edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma","volume":"80","author":"Basolo","year":"2023","journal-title":"Endocrine."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1794","article-title":"Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071728","article-title":"Predictive factors for RAI-refractory disease and short overall survival in PDTC","volume":"13","author":"Kersting","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02352-z","article-title":"Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status","volume":"47","author":"Schubert","year":"2024","journal-title":"J Endocrinol Invest."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej14-0181","article-title":"Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy","volume":"61","author":"Ito","year":"2014","journal-title":"Endocr J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13550-022-00917-8","article-title":"Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study","volume":"12","author":"Liu","year":"2022","journal-title":"EJNMMI Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0075","article-title":"Clinical, pathological, and molecular profiling of radioactive iodine refractory differentiated thyroid cancer","volume":"29","author":"Shobab","year":"2019","journal-title":"Thyroid."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.549882","article-title":"Clinical, pathological, and molecular characteristics correlating to the occurrence of radioiodine refractory differentiated thyroid carcinoma: A systematic review and meta-analysis","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02076-6","article-title":"Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features","volume":"46","author":"Lorusso","year":"2023","journal-title":"J Endocrinol Invest."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11145","article-title":"Predicting recurrence of papillary thyroid cancer using the eighth edition of the AJCC\/UICC staging system","volume":"106","author":"Chereau","year":"2019","journal-title":"Br J Surg"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1709736\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:35:13Z","timestamp":1773207313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1709736\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":32,"alternative-id":["10.3389\/fendo.2026.1709736"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1709736","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1709736"}}